Stock ALOPM ONCODESIGN PRECISION MEDICINE
Add to a list
To use this feature you must be a member
Log inSign up

Financials Oncodesign Precision Medicine

Equities

ALOPM

FR001400CM63

Biotechnology & Medical Research

Real-time Euronext Paris
Other stock markets
 09:37:43 2024-05-22 am EDT 		5-day change 1st Jan Change
1.225 EUR -5.77% Intraday chart for Oncodesign Precision Medicine -7.20% -32.32%
May. 15 Oncodesign Precision Medicine and Navigo Proteins GmbH Sign A Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents CI
Jan. 25 Oncodesign Precision Medicine: fundraising on the horizon CF

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 11.75 12.51 21.65 - -
Enterprise Value (EV) 1 11.75 12.51 30.15 27.95 58.25
P/E ratio - - -3.42 x -3.25 x -1.35 x
Yield - - - - -
Capitalization / Revenue 1.47 x 11.4 x 21.7 x 1.6 x 19.7 x
EV / Revenue 1.47 x 11.4 x 30.2 x 2.06 x 53 x
EV / EBITDA - -1.32 x -3.3 x 9.98 x -2.79 x
EV / FCF - - -2.99 x 12.4 x -3.15 x
FCF Yield - - -33.5% 8.05% -31.8%
Price to Book - - 43.3 x -3.33 x -0.95 x
Nbr of stocks (in thousands) 6,913 6,913 16,657 - -
Reference price 2 1.700 1.810 1.300 1.300 1.300
Announcement Date 4/13/23 3/26/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 8 1.1 1 13.55 1.1
EBITDA 1 - -9.5 -9.15 2.8 -20.9
EBIT 1 - -9.9 -10.4 1.5 -21.4
Operating Margin - -900% -1,040% 11.07% -1,945.45%
Earnings before Tax (EBT) 1 - - -8.4 -8.9 -21.2
Net income 1 -0.2 - -6.9 -7.3 -17.5
Net margin -2.5% - -690% -53.87% -1,590.91%
EPS 2 - - -0.3800 -0.4000 -0.9600
Free Cash Flow 1 - - -10.1 2.25 -18.5
FCF margin - - -1,010% 16.61% -1,681.82%
FCF Conversion (EBITDA) - - - 80.36% -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 4/13/23 3/26/24 - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt 1 - - 8.5 6.3 36.6
Net Cash position 1 - - - - -
Leverage (Debt/EBITDA) - - -0.929 x 2.25 x -1.751 x
Free Cash Flow 1 - - -10.1 2.25 -18.5
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share 2 - - 0.0300 -0.3900 -1.370
Cash Flow per Share 2 - - -0.3600 -0.3800 -0.9400
Capex 1 - - 1.2 1.15 1.4
Capex / Sales - - 120% 8.49% 127.27%
Announcement Date 4/13/23 3/26/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Oncodesign Precision Medicine

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.3 EUR
Average target price
2.48 EUR
Spread / Average Target
+90.77%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ONCODESIGN PRECISION MEDICINE Stock Oncodesign Precision Medicine
-32.32% 23.51M
MODERNA, INC. Stock Moderna, Inc.
+44.48% 55.07B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.86% 41.79B
LONZA GROUP AG Stock Lonza Group AG
+44.19% 40.22B
CELLTRION, INC. Stock Celltrion, Inc.
-7.59% 28.17B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.30% 26.28B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.83% 18.93B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+7.15% 13.03B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.40% 12.26B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.15% 12.21B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALOPM Stock
  4. Financials Oncodesign Precision Medicine
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW